B+
Bull case
20%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
IMA
ImageneBioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$3.80
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.8
Score
AI commentary
Cautious monitoring view. The packet contains strong company-source operating context but no recent news, validated analyst revisions, post-release price reaction, or sufficient social/options data; zero sentiment fields indicate unavailable measurements, not neutral observations. The deterministic score points negative despite higher evidence quality and catalyst density than the prior baseline. No new clinical result is established.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystPlanned Phase 2 alopecia areata trial initiationHigh impact
ImageneBio planned to initiate a Phase 2 olevaprubart trial in alopecia areata during 2026. Initiation would confirm execution of the expanded development plan, but the August update projected initial data only in 2028; trial start is not an efficacy readout. The plan appears in the company release furnished with its August 5 8-K [#8-K-2026-08-05] [#SEC-8K-2026-08-05].
2027-12-31eventADAPTIVE Phase 2b atopic dermatitis toplineHigh impact
The company anticipated fourth-quarter 2027 topline data from the amended Phase 2b ADAPTIVE study. Its August release said the study was progressing and that an independent monitoring committee recommended continuing without changes in July; neither establishes efficacy. This is the principal clinical value inflection [#SEC-8K-2026-08-05].
2028-03-31catalystRunway versus the clinical timetableHigh impact
ImageneBio reported $136.2 million of cash, cash equivalents and marketable securities at June 30, 2026, after an April private placement, and expected funding for planned operations into the first quarter of 2028. Spending, trial timing or additional financing could change that outlook; the runway is a monitoring point, not proof that development will be completed without dilution [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology